
Sign up to save your podcasts
Or
Quick rundown of an important rheumatology RCT this week, discussing the IL-5 inhibitor benralizumab for the treatment of relapsing/refractory EGPA.
MANDARA Study: https://www.nejm.org/doi/full/10.1056/NEJMoa2311155
4.9
109109 ratings
Quick rundown of an important rheumatology RCT this week, discussing the IL-5 inhibitor benralizumab for the treatment of relapsing/refractory EGPA.
MANDARA Study: https://www.nejm.org/doi/full/10.1056/NEJMoa2311155
313 Listeners
488 Listeners
113 Listeners
3,317 Listeners
1,071 Listeners
115 Listeners
169 Listeners
506 Listeners
317 Listeners
60 Listeners
6 Listeners
365 Listeners
170 Listeners
5 Listeners
19 Listeners